

**Appendix 10 (as supplied by the authors): Incidence and Risk of All-Cause Death, Major Adverse Cardiac Events, and Hospitalization for Acute Kidney Injury and Hyperkalemia Among Patients Using ARBs and ACEIs After Propensity Score Matching**

	ARB cohort			ACEI cohort (As Reference)			Crude	Competing Risk <sup>‡</sup>
	No. of Event	Person-years	Incidence rate*	No. of Event	Person-years	Incidence rate*	Hazard Ratio (95% CI)	Hazard Ratio (95% CI)
<b>Intention-to-treat analysis</b>								
All-cause death	1,421	54,620	26.02	1,500	54,129	27.71	0.94 (0.87-1.01)	-
Major adverse cardiac events	944	52,004	18.15	978	51,409	19.02	0.95 (0.87-1.04)	0.96 (0.88-1.05)
Myocardial infarction	317	53,867	5.88	306	53,501	5.72	1.03 (0.88-1.20)	1.03 (0.88-1.21)
Ischemic Stroke	685	52,664	13.01	720	51,966	13.86	0.94 (0.85-1.04)	0.94 (0.85-1.05)
Cardiovascular death	417	54,581	7.64	408	54,103	7.54	1.01 (0.88-1.16)	-
Hospitalization for acute kidney injury	671	53,311	12.59	656	52,829	12.42	1.01 (0.91-1.13)	1.02 (0.91-1.13)
Hospitalization for hyperkalemia	320	53,892	5.94	314	53,325	5.89	1.01 (0.86-1.18)	1.01 (0.87-1.18)
<b>As-treated analysis</b>								
All-cause death	252	32,765	7.69	163	21,546	7.57	1.06 (0.87-1.29)	-
Major adverse cardiac events	463	32,036	14.45	321	21,213	15.13	0.96 (0.83-1.11)	1.03 (0.89-1.19)
Myocardial infarction	139	32,583	4.27	788	21,486	3.63	1.16 (0.87-1.53)	1.25 (0.95-1.66)
Ischemic Stroke	342	32,201	10.62	251	21,272	11.80	0.91 (0.77-1.08)	0.98 (0.84-1.16)
Cardiovascular death	41	32,762	1.25	19	21,546	0.88	1.41 (0.81-2.44)	-
Hospitalization for acute kidney injury	276	32,456	8.50	154	21,430	7.19	1.19 (0.98-1.46)	1.27 (1.05-1.55)
Hospitalization for hyperkalemia	122	32,602	3.74	81	21,438	3.78	1.02 (0.77-1.35)	1.09 (0.83-1.44)

\* per 10<sup>3</sup> person-years.

<sup>‡</sup>Death as a competing risk in this model.

Abbreviations: CI, confidence interval; ARB, Angiotensin II receptor blockers; ACEI, angiotensin-converting-enzyme inhibitors.

